Clorox Lowers Annual Profit Forecast Amid Rising Costs
Clorox shares fell 5.64% and hit a 52-week low following the company's announcement of a reduced annual profit forecast.
The company has lowered its annual adjusted earnings per share forecast to between $5.45 and $5.65, down from $5.95 to $6.30, indicating significant profitability challenges due to weak demand and rising costs. Clorox also anticipates a 6% decline in annual net sales, reflecting its adaptability in navigating market changes, despite reporting adjusted earnings of $1.64 per share for the third quarter, which exceeded analyst expectations of $1.55.
This adjustment in profit outlook raises concerns about Clorox's ability to maintain its market position amid increasing cost pressures and declining sales, potentially impacting investor confidence.
Trade with 70% Backtested Accuracy
Analyst Views on CLX
About CLX
About the author

- Market Decline: The S&P 500 fell 2.64% and the Nasdaq 100 dropped 4.77%, indicating a significant loss of investor confidence in tech stocks, particularly as AI infrastructure and semiconductor companies faced sell-offs, which could impact future investment strategies.
- Strong Employment Data: US nonfarm payrolls rose by 172,000 in May, significantly exceeding expectations of 88,000, while the unemployment rate held steady at 4.3%, potentially prompting the Fed to consider a rate hike at the upcoming meeting, thereby affecting market liquidity and investor sentiment.
- Rising Bond Yields: The 10-year Treasury yield climbed to 4.55%, a two-week high, reflecting heightened expectations for future rate hikes, which may lead to capital outflows from the stock market, further exacerbating market volatility.
- Tech Stock Retreat: Following Broadcom's disappointing chip sales outlook, Marvell and Micron stocks plummeted over 16% and 13%, respectively, suggesting that the market's overly optimistic sentiment towards tech stocks may be correcting, impacting investor confidence.
- Strong Market Performance: The S&P 500 rose by 0.22%, the Dow Jones Industrial Average increased by 0.72%, and the Nasdaq 100 climbed by 0.36%, with all three indices reaching new all-time highs, reflecting market confidence in economic recovery.
- Tech Stocks Lead Gains: Dell Technologies surged 32% after reporting Q1 total revenue of $43.84 billion, significantly exceeding the consensus estimate of $35.52 billion, and raised its 2027 revenue forecast to between $165 billion and $169 billion, indicating strong market demand and growth potential.
- Positive Economic Data: The May Chicago PMI rose by 13.5 to 62.7, far surpassing expectations of 50.3, marking the fastest expansion pace in 4.25 years, which further bolstered market confidence in stocks.
- Oil Price Decline Benefits Stocks: Crude oil prices fell over 1% to a five-week low due to a preliminary agreement between the US and Iran, easing inflation concerns and supporting the upward trend in the stock market.
- Microsoft's Growth Potential: Microsoft (MSFT) boasts a market cap exceeding $3 trillion, with an average annual growth of 21% over the past 15 years; despite a recent 12% drop, its forward P/E ratio of 22 is attractive compared to the five-year average of 30.
- Healthcare Sector Leader: Becton, Dickinson (BD) leads in medical devices, producing over 34 billion devices annually, with a 2025 report indicating 125 new product launches and a dividend yield of 2.8%, ensuring stable revenue streams.
- Clorox's Dividend Appeal: Clorox (CLX) has seen a 25% stock price decline, resulting in a forward P/E ratio of 13, below the five-year average of 24, and a dividend yield of 5.1%, making it appealing for long-term investors.
- Market Challenges and Responses: Despite facing cost pressures from rising oil prices, Clorox's management reported positive performance in consumer categories, indicating brand resilience and sustained market demand.
- Microsoft's Stock Appeal: With a market value exceeding $3 trillion and an average annual growth rate of 21% over the past 15 years, Microsoft's recent 12% drop has lowered its forward P/E ratio to 22, significantly below the five-year average of 30, indicating strong investment potential.
- BD's Steady Growth: Becton, Dickinson produces over 34 billion medical devices annually, and its 2025 report highlights the launch of over 125 new products and an additional $1.3 billion in revenue from more than 20 acquisitions, showcasing its robust innovation in the medical supply sector.
- Clorox's Dividend Appeal: Clorox boasts a dividend yield of 5.1% and has increased its payout for 48 consecutive years; despite a more than 25% drop in stock price over the past year, its forward P/E ratio stands at 13, well below the five-year average of 24, suggesting investment value.
- Market Environment Impact: Facing rising oil prices that could cost over $20 million in quarterly gross profit, Clorox is working on efficiency improvements, with the CEO noting that consumer spending on brands remains strong, indicating resilience in challenging market conditions.

- Executive Change: Clorox announced that CEO Linda Rendle is stepping down for health reasons, prompting the board to initiate a comprehensive search for a new CEO, indicating challenges in leadership stability for the company.
- Transition Plan: Rendle will remain in her role until a successor is appointed and will provide advisory support during the transition period, aiming to ensure continuity and stability in company operations.
- Market Reaction: This executive change may impact Clorox's stock price, as investor concerns about the company's future strategic direction could intensify, especially following the company's lowered FY26 outlook.
- Industry Context: Clorox faces intense competition and market pressures in the consumer goods sector, and the board's decisions will have significant implications for the company's long-term strategic development.
- Kimberly-Clark Financial Performance: In FY 2025, Kimberly-Clark reported nearly $16.4 billion in revenue, down from $16.8 billion the previous year, with a net income of approximately $2.0 billion and a net margin of 12.2%, indicating profitability pressures amid shifting consumer demand, necessitating attention to its international business sale and potential merger impacts.
- Clorox Profit Recovery: Clorox generated about $7.1 billion in revenue for FY 2025, with net income significantly rising to approximately $810 million and a net margin of 11.4%, reflecting a gradual recovery in profitability post-pandemic, despite facing customer concentration risks and cybersecurity challenges.
- Competition and Risk Analysis: Kimberly-Clark faces intense competition from Procter & Gamble and generic brands, with geopolitical and currency fluctuations impacting its international sales, while Clorox's 27% sales dependency on Walmart poses pricing pressures, compounded by ongoing recovery from a recent cyberattack.
- Valuation Comparison: Kimberly-Clark's forward P/E ratio stands at 13.2x, making it more attractive compared to Clorox's 17.4x, although both are below sector averages, prompting investors to weigh potential merger risks against market performance.










